The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline. - Wikidata - wikimedia - TriplyDB

The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline.

The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline.

http://www.wikidata.org/entity/Q34215058

about

Proteomics and peptidomics: moving toward precision medicine in urological malignancies Porous bead-based diagnostic platforms: bridging the gaps in healthcare Overview of proteomics studies in obstructive sleep apnea Applications of targeted proteomics in systems biology and translational medicine Proteomics investigations of HDL: challenges and promise Targeted proteomics for biomarker discovery and validation of hepatocellular carcinoma in hepatitis C infected patients Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry Determination of variation parameters as a crucial step in designing TMT-based clinical proteomics experiments An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers.Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: an NCI-CPTC initiative perspective.Interlaboratory study characterizing a yeast performance standard for benchmarking LC-MS platform performance.Applying proteomics to the diagnosis and treatment of ALS and related diseases.Automated screening of monoclonal antibodies for SISCAPA assays using a magnetic bead processor and liquid chromatography-selected reaction monitoring-mass spectrometry.Recent cerebrospinal fluid biomarker studies of Alzheimer's disease.Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma.Towards proteome standards: the use of absolute quantitation in high-throughput biomarker discovery.Selective enrichment and sensitive detection of peptide and protein biomarkers in human serum using polymeric reverse micelles and MALDI-MS The evolving role of mass spectrometry in cancer biomarker discovery Mass-spectrometry-based clinical proteomics--a review and prospective.Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics.Ensembles of protein termini and specific proteolytic signatures as candidate biomarkers of disease.Restructuring proteomics through verification Protein analysis by shotgun/bottom-up proteomics The importance of early life in childhood obesity and related diseases: a report from the 2014 Gravida Strategic Summit Computational biomarker pipeline from discovery to clinical implementation: plasma proteomic biomarkers for cardiac transplantation.Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry.Identification of a novel proteoform of prostate specific antigen (SNP-L132I) in clinical samples by multiple reaction monitoring Biomarker discovery for early detection of hepatocellular carcinoma in hepatitis C-infected patients.Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatography-multiple- reaction-monitoring mass spectrometry From lost in translation to paradise found: enabling protein biomarker method transfer by mass spectrometry Anti-peptide monoclonal antibodies generated for immuno-multiple reaction monitoring-mass spectrometry assays have a high probability of supporting Western blot and ELISA.Biomarkers: hopes and challenges in the path from discovery to clinical practice.Using data-independent, high-resolution mass spectrometry in protein biomarker research: perspectives and clinical applications.A targeted proteomics-based pipeline for verification of biomarkers in plasma Accurate quantification of cardiovascular biomarkers in serum using Protein Standard Absolute Quantification (PSAQ™) and selected reaction monitoring Targeted proteomics: a bridge between discovery and validation.A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease.Large-Scale Interlaboratory Study to Develop, Analytically Validate and Apply Highly Multiplexed, Quantitative Peptide Assays to Measure Cancer-Relevant Proteins in Plasma.Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma Serum Glycoprotein Biomarker Discovery and Qualification Pipeline Reveals Novel Diagnostic Biomarker Candidates for Esophageal Adenocarcinoma.

P2860

Q26749401-5769F40B-8486-4C04-916A-65697414D410 Q26829421-7BA312B6-DF00-438E-B94A-18CF36551F40 Q26830581-A854470A-17E1-4F3E-9556-163F71583CB2 Q26852271-B55331D9-963C-4383-8DAA-297E2EBA5F9F Q27000995-ED50DA27-05BF-49B6-BBF9-60D2F8B6A019 Q28085015-5BDDC292-5660-479A-A035-FFEF96596D91 Q28395328-3B3E95CC-1319-475F-A3EC-F5DEB2003630 Q28544078-001A8629-F873-4751-B66E-463D9893DFCA Q33597992-6E0E966E-8336-4CB8-809F-F00E3F9C0409 Q33669587-FEEE8F22-461F-4FBB-9506-9F53CADBF072 Q33697735-936AAC1B-9CF9-4591-9E66-8C657FBAB9F8 Q33719446-18801FEF-C701-4573-B2D6-4A6FB3E6A030 Q33731947-5F5CF30B-0424-440F-B10F-6B82D2F24A8E Q33766323-B6AA25E7-0E6D-4E8C-9CC5-83992F492BCA Q33794491-5DDF72E5-4C93-4827-841E-71E0C4145A10 Q33912503-7E5E1DBC-ED6D-4228-A4B2-5D99FF6781E2 Q34109421-EC964715-F1E2-4E6E-8F58-0DA2516ED3D2 Q34215422-ECC4F0D3-8B91-466D-ABAC-354663838864 Q34252113-846AAEA9-6293-4166-9756-97C5E4037897 Q34333925-E2759DBB-DB1D-4463-A423-88B9C97E8F5D Q34402330-67730C46-D931-4475-891F-4E904CF202E3 Q34585479-6F8B4FF2-BE3E-4499-9942-EB9F500FC2F4 Q34600986-23A69ACB-C00D-4566-B8ED-1FC80D919A75 Q34629295-AA4D1027-3B22-4825-AA11-289016FA51CA Q34671668-960BF586-D08C-4C58-B7D4-1A9BE27C34A5 Q34751690-8B0924E3-1396-40B1-B797-76BEF75505DC Q34810177-83513182-49AF-4079-93A9-98FBE72B6F2F Q34979196-5D4FA024-B2F3-4701-97C6-F0EEA7EAD938 Q35012598-69582872-BD58-4516-8572-9256CB16701F Q35044673-165AA05D-339B-49FC-8A3C-7C4DC9919B74 Q35148573-D5AF091F-F659-4027-A710-E05F83355D14 Q35471494-392F2F3F-D4E9-4DDF-8E1B-A2DED81C4EE1 Q35518214-28FBB342-60EA-4F1E-9611-EDCA570F2097 Q35596338-C3570E74-264B-4278-9E79-03BB256E26BB Q35751624-CC605DAD-2231-415F-9488-734823E19D1E Q35815142-2D421005-5C9A-460A-A408-A5D2C7359604 Q36006127-B82B5A0E-1498-4C89-98FD-B49124813BC6 Q36040373-090959A2-13C5-49F5-B58F-5572DD3C2376 Q36209072-47165C2C-85CB-4AD3-A5C6-56D53AE59578 Q36263057-BA365ACE-D11A-4070-933C-0FC8E953C26C

P2860

The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline.

http://www.wikidata.org/entity/Q34215058

description

2008 nî lūn-bûn

@nan

2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

The interface between biomarke ...... he protein biomarker pipeline.

@ast

The interface between biomarke ...... he protein biomarker pipeline.

@en

The interface between biomarke ...... he protein biomarker pipeline.

@nl

type

label

The interface between biomarke ...... he protein biomarker pipeline.

@ast

The interface between biomarke ...... he protein biomarker pipeline.

@en

The interface between biomarke ...... he protein biomarker pipeline.

@nl

prefLabel

The interface between biomarke ...... he protein biomarker pipeline.

@ast

The interface between biomarke ...... he protein biomarker pipeline.

@en

The interface between biomarke ...... he protein biomarker pipeline.

@nl

P1433

Q34215058-F1D12747-075C-45E4-8DB3-E4C1040F361A

P1476

Q34215058-0F7005C3-542D-4F4E-8117-411A58F8CF7A

P2093

Q34215058-7BC2083F-BE7C-4EC0-8F8C-59EC24B922C3

Q34215058-AF3F9BC3-705B-45FB-99B2-58FD45444A6A

Q34215058-EC1BDDF3-6651-43BE-BABF-A903B06C212C

P2860

Q34215058-01EA75DF-916C-4134-A5B2-317F3786F3DC

Q34215058-05B5474D-7098-49B4-B2FD-07A5957A6A27

Q34215058-12B406ED-B269-4C3E-B0E5-38787638657B

Q34215058-12D63B7F-B4B1-4A55-ACBC-38061089D311

Q34215058-152485F6-0312-4A1C-B162-AAA9ECC18C2D

Q34215058-208CC8E0-C8BA-4615-9EC6-8AEF941BC59F

Q34215058-285330EF-35A1-49E6-8A8D-6A729B7319AD

Q34215058-398FA86D-4247-40B1-A2BA-2B15AE23D22C

Q34215058-3D61967B-3DB0-41D2-B5B8-40121E757E91

Q34215058-3F6A1C3A-D72F-4F25-B64A-4FB0A35EE7D5

P304

Q34215058-66488F10-6F56-4420-874A-099F6BDF3FD9

P31

Q34215058-B8ED0402-15E8-4435-B2CF-B39378EAE0EC

P356

Q34215058-532BA356-FD9B-4930-8D39-20CAB1A4E55E

P433

Q34215058-CAB87718-A77F-4ABB-ABBF-DDF07A81CA8B

P478

Q34215058-80C4BD61-C300-48B2-8B3A-16E1BCE8D821

P50

Q34215058-EFD74333-516E-4D26-AB45-B0B7E32C0905

P577

Q34215058-2A8B9F3F-EEA2-4B8F-981E-F19F63026967

P5875

Q34215058-5E3B0D18-9EDE-4BB9-946C-AC245FD33DD4

P698

Q34215058-D8AFE00F-50B3-430C-A0BA-0203BF64EEE1

P921

Q34215058-E0F33364-FE87-4A5B-B885-D03E61C07DDA

P932

Q34215058-DE3C013A-113B-4A09-A6F5-A794DF0FEB5C

P356

P1433

Proteomics - Clinical Applications

P1476

The interface between biomarke ...... he protein biomarker pipeline.

@en

P2093

Amanda G Paulovich

http://www.w3.org/2001/XMLSchema#string

Jeffrey R Whiteaker

http://www.w3.org/2001/XMLSchema#string

Pei Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS

Comparing protein abundance and mRNA expression levels on a genomic scale

PRIDE: a public repository of protein and peptide identifications for the proteomics community

The PeptideAtlas project

Global analysis of protein expression in yeast

Correlation between protein and mRNA abundance in yeast

The price of innovation: new estimates of drug development costs

The human plasma proteome: history, character, and diagnostic prospects

hORFeome v3.1: a resource of human open reading frames representing over 10,000 human genes

Estimating the cost of new drug development: is it really 802 million dollars?

P304

1386-1402

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PRCA.200780174

http://www.w3.org/2001/XMLSchema#string

P433

10-11

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Andrew N Hoofnagle

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47545413

http://www.w3.org/2001/XMLSchema#string

P698

20976028

http://www.w3.org/2001/XMLSchema#string

P921

P932

2957839

http://www.w3.org/2001/XMLSchema#string